company background image
VACC

Vaccitech NasdaqGM:VACC Stock Report

Last Price

US$2.50

Market Cap

US$94.4m

7D

1.8%

1Y

-42.1%

Updated

07 Jun, 2023

Data

Company Financials +

VACC Stock Overview

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers.

VACC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Vaccitech plc Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vaccitech
Historical stock prices
Current Share PriceUS$2.50
52 Week HighUS$7.45
52 Week LowUS$2.02
Beta0.17
1 Month Change6.84%
3 Month Change-15.25%
1 Year Change-42.13%
3 Year Changen/a
5 Year Changen/a
Change since IPO-82.27%

Recent News & Updates

Recent updates

Vaccitech's (NASDAQ:VACC) Earnings Are Of Questionable Quality

Nov 17
Vaccitech's (NASDAQ:VACC) Earnings Are Of Questionable Quality

Vaccitech promotes Gemma Brown to CFO

Sep 20

Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts

Aug 15
Analysts Just Made An Incredible Upgrade To Their Vaccitech plc (NASDAQ:VACC) Forecasts

Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Aug 13
Vaccitech plc Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Vaccitech GAAP EPS of $0.41, revenue of $17.06M

Aug 09

Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%

May 19
Growth Investors: Industry Analysts Just Upgraded Their Vaccitech plc (NASDAQ:VACC) Revenue Forecasts By 51%

Vaccitech: Aiming For A Cure In Chronic Hepatitis B

Apr 03

Vaccitech: The Next Big Vaccine Trade

Jun 27

Vaccitech EPS misses by $0.69, beats on revenue

Jun 14

Shareholder Returns

VACCUS BiotechsUS Market
7D1.8%2.3%2.5%
1Y-42.1%11.1%1.3%

Return vs Industry: VACC underperformed the US Biotechs industry which returned 11.1% over the past year.

Return vs Market: VACC underperformed the US Market which returned 1.3% over the past year.

Price Volatility

Is VACC's price volatile compared to industry and market?
VACC volatility
VACC Average Weekly Movement12.1%
Biotechs Industry Average Movement11.2%
Market Average Movement6.6%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: VACC is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 12% a week.

Volatility Over Time: VACC's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201633Bill Enrighthttps://www.vaccitech.co.uk

Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company’s therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection.

Vaccitech plc Fundamentals Summary

How do Vaccitech's earnings and revenue compare to its market cap?
VACC fundamental statistics
Market CapUS$94.39m
Earnings (TTM)-US$15.43m
Revenue (TTM)US$30.15m

3.2x

P/S Ratio

-6.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VACC income statement (TTM)
RevenueUS$30.15m
Cost of RevenueUS$41.46m
Gross Profit-US$11.31m
Other ExpensesUS$4.12m
Earnings-US$15.43m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.40
Gross Margin-37.51%
Net Profit Margin-51.19%
Debt/Equity Ratio0%

How did VACC perform over the long term?

See historical performance and comparison